Madison Muller, Bloomberg News health reporter, says that the failure of a long-shot trial to see if the pill form of Novo Nordisk’s weight loss drug Ozempic impacted Alzheimer’s was the latest in a long string of disappointments for investors into the pharmaceutical company. Novo Nordisk is down over 50% on the year. (Source: Bloomberg)
www.bloomberg.com
#Novo #Shares #Drop #Ozempic #Pill #Fails #Alzheimers #Trial
Novo Shares Drop as Ozempic Pill Fails Alzheimer’s Trial
